Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

@article{Cartron2002TherapeuticAO,
  title={Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.},
  author={Guillaume Cartron and Laurent Dacheux and Gilles Andr{\'e} Salles and Philippe Solal-C{\'e}ligny and Pierre Bardos and Philippe Colombat and Herv{\'e} Watier},
  journal={Blood},
  year={2002},
  volume={99 3},
  pages={
          754-8
        }
}
Given that the FcgammaRIIIa receptor 158V allotype displays a higher affinity for human immunoglobulin G1 and increased antibody-dependent cellular cytotoxicity, the aim of this study was to determine the influence of that FCGR3A polymorphism on the therapeutic response to rituximab, an anti-CD20 humanized immunoglobulin G1 increasingly used in the treatment of non-Hodgkin lymphomas. The FCGR3A-158V/F genotype was determined in 49 patients having received rituximab for a previously untreated… 
View on PubMed
bloodjournal.org
1,918 Citations
Highly Influential Citations
61
Background Citations
503
Methods Citations
19
Results Citations
62

1,918 Citations

Citation Type

Citation Type

Original article. Correlation of FcγRIIIa polymorphisms and responses to rituximab in Thai population
TLDR
FcγRIIIa polymorphism and the primary response in NHL patients tend to correlate and provide useful information to understand beneficial response of rituximab as well as other IgG1 therapeutic antibody in Thai patients.
The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients
TLDR
The findings of the present study indicate that FcγR polymorphisms have no influence on the survival of DLBCL patients.
Correlation of Fc?RIIIa polymorphisms and responses to rituximab in Thai population
TLDR
The frequencies of Fc?RIIIa polymorphism and the primary response in NHL patients tend to correlate and the results provide useful information to understand beneficial response of rituximab as well as other IgG1 therapeutic antibody in Thai patients.
Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab
TLDR
This study is the first to determine whether inhibitory FcγRIIb play a role in rituximab's anti-tumor effect in humans.
Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia
TLDR
A stringent phase II response evaluation of children and adolescents with B-NHL after one dose of rituximab monotherapy showed a significant association between the ritUXimab response rate and FCGR polymorphisms, which support the hypothesis that FC GR polymorphisms represent patient-specific parameters that influence the response to ritudine.
FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
Correlation of FcγRIIIa Polymorphisms and the Response to Rituximab in Thai Population
TLDR
The results provide the distribution of FcγRIIIa polymorphisms in Thai population which seems to differ from other Asian countries.
Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia.
  • S. Treon, M. Hansen, +7 authors E. Fox
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
TLDR
The results of these studies support a predictive role for FcγRIIIA-158 polymorphisms and major responses to rituximab in patients with Waldenstrom's macroglobulinemia treated with ritUXimab.
Effect of FCGR2A and FCGR3A variants on CLL outcome.
TLDR
The results suggest that FCGR2A and FCGR3A polymorphisms do not significantly influence the outcomes of relapsed or refractory CLL patients treated with FC or the monoclonal antibody regimen R-FC.
Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis
TLDR
The results suggest that FCGR3A polymorphism may predict more effective disease activity reduction by RTX and carrying the V allele may also be associated with better therapeutic response in Hungarian patients with RA.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Immunoglobulin G Fc-receptor (FcγR) IIA and IIIB polymorphisms related to disability in MS
TLDR
The results implicate FcγRIIIB and to a lesser extent F cγRIIA as disease-modifying genes in MS and a more effective processing of circulating immune complexes may be one mechanism for better clinical outcome in MS.
IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
TLDR
Likelihood of tumor response was associated with a follicular histology, with the ability to sustain a high serum level of antibody after the first infusion, and with a longer duration of remission to prior chemotherapy, and IDEC-C2B8 has a better safety profile.
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
TLDR
Likelihood of tumor response was associated with a follicular histology, with the ability to sustain a high serum level of antibody after the first infusion, and with a longer duration of remission to prior chemotherapy, and IDEC-C2B8 has a better safety profile.
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
TLDR
The results demonstrate that the previously described C1q binding motif in murine IgG2b constituting residues E318, K320, and K322 is not applicable to a human IgG1 when challenged with either human, rabbit, or guinea pig complement and suggest that there are species-specific differences in the C 1q binding site of Igs.
A novel PCR-based method for direct Fcγ receptor IIIa (CD16) allotyping
A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.
TLDR
Initial analysis of 200 patients with SLE indicates a strong association of the low binding phenotype with disease, especially in patients with nephritis who have an underrepresentation of the homozygous high binding phenotype.
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
TLDR
The response rate of 48% with IDEC-C2B8 is comparable to results with single-agent cytotoxic chemotherapy, and further investigation of this agent is warranted, including its use in conjunction with standard chemotherapy.
Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse.
TLDR
Analyzing FcgammaR phenotypes demonstrated that patients with Wegener's granulomatosis were more prone to disease relapse in the first 5 years after diagnosis if they were homozygous for both the R131 form of FcGammaRIIa and the F158 form ofFcgamMARIIIa, which may be relevant to the chronic nasal carriage of S aureus.
Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma.
TLDR
Pharmacokinetic data suggests that certain subsets of patients may possibly benefit from increased dosing of Rituximab and studies to address this are currently underway.
FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype
TLDR
Differences in IgG binding among the three Fc gammaRIIIa-48L/R/H isoforms are a consequence of the linked, biallelic Fc Gamma receptor IIIa-158V/F polymorphism at amino-acid position 158.
...
1
2
3
4
5
...